Silicon Valley Biosystems (SV Bio) has changed its name to Lifecode. The new name is consistent with the company's mission to improve the lives of patients by providing concise, accurate and actionable molecular information. Lifecode also has released its flagship next generation sequencing (NGS)-based oncology assay, the Pan Cancer Somatic Panel (PCSP), to a select group of physicians nationwide in advance of a broad launch later this spring.

Lifecode is developing a portfolio of NGS-based cancer assays, including the Pan Cancer Somatic Panel. Lifecode's Laboratory Developed Tests (LDT's) are developed exclusively on an NGS platform, utilizing a variety of machine learning techniques, proprietary algorithms and custom annotation and curation tools to accurately detect and interpret genomic alterations in patient tumor samples.

"As we move into this new era of personalized medicine in oncology, Lifecode will help to drive this transition using the most advanced tools in genome-guided medicine. Our goal is to provide accurate and actionable information for use in both near and long-term treatment decisions," said Chris Rivest, CEO of Lifecode. "As NGS capabilities have improved, there has been an exponential increase the quantity of clinical and research data regarding the molecular basis of cancer. Our goal at Lifecode is to help physicians manage the flood of information by leveraging our world class computational tools, algorithms and data science."